Top

Published in:

Open Access 01-07-2014 | Original Paper

Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology

Authors: Kathrin Doppler, Sönke Ebert, Nurcan Üçeyler, Claudia Trenkwalder, Jens Ebentheuer, Jens Volkmann, Claudia Sommer

Published in: Acta Neuropathologica | Issue 1/2014

Abstract

The deposition of alpha-synuclein in the brain, the neuropathological hallmark of Parkinson’s disease (PD), follows a distinct anatomical and temporal sequence. This study aimed to characterize alpha-synuclein deposition in cutaneous nerves from patients with PD. We further strived to explore whether peripheral nerve involvement is intrinsic to PD and reflective of known features of brain pathology, which could render it a useful tool for pathogenetic studies and pre-mortem histological diagnosis of PD. We obtained skin biopsies from the distal and proximal leg, back and finger of 31 PD patients and 35 controls and quantified the colocalization of phosphorylated alpha-synuclein in somatosensory and autonomic nerve fibers and the pattern of loss of different subtypes of dermal fibers. Deposits of phosphorylated alpha-synuclein were identified in 16/31 PD patients but in 0/35 controls (p < 0.0001). Quantification of nerve fibers revealed two types of peripheral neurodegeneration in PD: (1) a length-dependent reduction of intraepidermal small nerve fibers (p < 0.05) and (2) a severe non-length-dependent reduction of substance P-immunoreactive intraepidermal nerve fibers (p < 0.0001). The latter coincided with a more pronounced proximal manifestation of alpha-synuclein pathology in the skin. The histological changes did not correlate with markers of levodopa toxicity such as vitamin B12 deficiency. Our findings suggest that loss of peripheral nerve fibers is an intrinsic feature of PD and that peripheral nerve changes may reflect the two types of central alpha-synuclein-related PD pathology, namely neuronal death and axonal degeneration. Detection of phosphorylated alpha-synuclein in dermal nerve fibers might be a useful diagnostic test for PD with high specificity but low sensitivity.

Available only for authorised users

Beach TG, Adler CH, Dugger BN et al (2013) Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol 72:130–136PubMedCentralCrossRefPubMed

Braak H, de Vos RA, Bohl J et al (2006) Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 396:67–72CrossRefPubMed

Braak H, Del Tredici K, Rub U et al (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211CrossRefPubMed

Braak H, Rub U, Gai WP et al (2003) Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110:517–536CrossRefPubMed

Ceravolo R, Cossu G, Bandettini di Poggio M et al (2013) Neuropathy and levodopa in Parkinson’s disease: evidence from a multicenter study. Mov Disord 28:1391–1397PubMed

Cheng HC, Ulane CM, Burke RE (2010) Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 67:715–725PubMedCentralCrossRefPubMed

Chu Y, Morfini GA, Langhamer LB et al (2012) Alterations in axonal transport motor proteins in sporadic and experimental Parkinson’s disease. Brain 135:2058–2073CrossRefPubMed

Dabby R, Djaldetti R, Shahmurov M et al (2006) Skin biopsy for assessment of autonomic denervation in Parkinson’s disease. J Neural Transm 113:1169–1176CrossRefPubMed

Del Tredici K, Braak H (2012) Lewy pathology and neurodegeneration in premotor Parkinson’s disease. Mov Disord 27:597–607CrossRefPubMed

10.

Del Tredici K, Braak H (2012) Spinal cord lesions in sporadic Parkinson’s disease. Acta Neuropathol 124:643–664CrossRefPubMed

11.

Doppler K, Werner C, Henneges C et al (2012) Analysis of myelinated fibers in human skin biopsies of patients with neuropathies. J Neurol 259:1879–1887CrossRefPubMed

12.

Dugger BN, Dickson DW (2010) Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies. Acta Neuropathol 120:633–639PubMedCentralCrossRefPubMed

13.

Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114(Pt 5):2283–2301CrossRefPubMed

14.

Fernandez A, de Ceballos ML, Rose S et al (1996) Alterations in peptide levels in Parkinson’s disease and incidental Lewy body disease. Brain 119(Pt 3):823–830CrossRefPubMed

15.

Folgoas E, Lebouvier T, Leclair-Visonneau L et al (2013) Diagnostic value of minor salivary glands biopsy for the detection of Lewy pathology. Neurosci Lett

16.

Gai WP, Halliday GM, Blumbergs PC et al (1991) Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson’s disease. Brain 114(Pt 5):2253–2267CrossRefPubMed

17.

Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement disorder society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–2170CrossRefPubMed

18.

Gorson KC, Herrmann DN, Thiagarajan R et al (2008) Non-length dependent small fibre neuropathy/ganglionopathy. J Neurol Neurosurg Psychiatry 79:163–169CrossRefPubMed

19.

Halliday GM, Li YW, Blumbergs PC et al (1990) Neuropathology of immunohistochemically identified brainstem neurons in Parkinson’s disease. Ann Neurol 27:373–385CrossRefPubMed

20.

Hilton D, Stephens M, Kirk L et al (2013) Accumulation of alpha-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease. Acta Neuropathol 127(2):235–241PubMed

21.

Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442CrossRefPubMed

22.

Hughes AJ, Daniel SE, Ben-Shlomo Y et al (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125:861–870CrossRefPubMed

23.

Hughes AJ, Daniel SE, Kilford L et al (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCentralCrossRefPubMed

24.

Ikemura M, Saito Y, Sengoku R et al (2008) Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 67:945–953CrossRefPubMed

25.

Jugel C, Ehlen F, Taskin B et al (2013) Neuropathy in Parkinson’s disease patients with intestinal levodopa infusion versus oral drugs. PLoS ONE 8:e66639PubMedCentralCrossRefPubMed

26.

Kimura J (ed) (2001) Electrodiagnosis in diseases of nerve and muscle: principles and practice. Oxford University Press, New York

27.

Kordower JH, Olanow CW, Dodiya HB et al (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 136:2419–2431CrossRefPubMed

28.

Kuljis RO, Martin-Vasallo P, Peress NS (1989) Lewy bodies in tyrosine hydroxylase-synthesizing neurons of the human cerebral cortex. Neurosci Lett 106:49–54CrossRefPubMed

29.

Lauria G, Bakkers M, Schmitz C et al (2010) Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst 15:202–207CrossRefPubMed

30.

Lauria G, Cornblath DR, Johansson O et al (2005) EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol 12:747–758CrossRefPubMed

31.

Lebouvier T, Neunlist M, Bruley des Varannes S et al (2010) Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms. PLoS ONE 5:e12728PubMedCentralCrossRefPubMed

32.

Lee HJ, Khoshaghideh F, Lee S et al (2006) Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. Eur J Neurosci 24:3153–3162CrossRefPubMed

33.

Li J, Bai Y, Ghandour K et al (2005) Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain 128:1168–1177CrossRefPubMed

34.

Litvan I, MacIntyre A, Goetz CG et al (1998) Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 55:969–978CrossRefPubMed

35.

Liu S, Sawada T, Lee S et al (2012) Parkinson’s disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. PLoS Genet 8:e1002537PubMedCentralCrossRefPubMed

36.

Magerl W, Krumova EK, Baron R et al (2010) Reference data for quantitative sensory testing (QST): refined stratification for age and a novel method for statistical comparison of group data. Pain 151:598–605CrossRefPubMed

37.

Mancini F, Comi C, Oggioni GD et al (2013) Prevalence and features of peripheral neuropathy in Parkinson’s disease patients under different therapeutic regimens. Parkinsonism Relat Disord 20(1):27–31CrossRefPubMed

38.

Miki Y, Tomiyama M, Ueno T et al (2010) Clinical availability of skin biopsy in the diagnosis of Parkinson’s disease. Neurosci Lett 469:357–359CrossRefPubMed

39.

Mu L, Sobotka S, Chen J et al (2013) Parkinson disease affects peripheral sensory nerves in the pharynx. J Neuropathol Exp Neurol 72:614–623PubMedCentralCrossRefPubMed

40.

Nolano M, Provitera V, Estraneo A et al (2008) Sensory deficit in Parkinson’s disease: evidence of a cutaneous denervation. Brain 131:1903–1911CrossRefPubMed

41.

Orimo S, Uchihara T, Nakamura A et al (2008) Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson’s disease. Brain 131:642–650CrossRefPubMed

42.

Prots I, Veber V, Brey S et al (2013) Alpha-synuclein oligomers impair neuronal microtubule-kinesin interplay. J Biol Chem 288(30):21742–21754CrossRefPubMed

43.

Rajabally YA, Martey J (2011) Neuropathy in Parkinson disease: prevalence and determinants. Neurology 77:1947–1950CrossRefPubMed

44.

Rinne JO, Rummukainen J, Paljarvi L et al (1989) Dementia in Parkinson’s disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 26:47–50CrossRefPubMed

45.

Rolke R, Baron R, Maier C et al (2006) Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain 123:231–243CrossRefPubMed

46.

Santos-Garcia D, de la Fuente-Fernandez R, Valldeoriola F et al (2012) Polyneuropathy while on duodenal levodopa infusion in Parkinson’s disease patients: we must be alert. J Neurol 259:1668–1672CrossRefPubMed

47.

Saporta MA, Katona I, Lewis RA et al (2009) Shortened internodal length of dermal myelinated nerve fibres in Charcot-Marie-Tooth disease type 1A. Brain 132:3263–3273PubMedCentralCrossRefPubMed

48.

Schrag A, Ben-Shlomo Y, Quinn N (2002) How valid is the clinical diagnosis of Parkinson’s disease in the community? J Neurol Neurosurg Psychiatry 73:529–534PubMedCentralCrossRefPubMed

49.

Shannon KM, Keshavarzian A, Dodiya HB et al (2012) Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases. Mov Disord 27:716–719CrossRefPubMed

50.

Siebert H, Kahle PJ, Kramer ML et al (2010) Over-expression of alpha-synuclein in the nervous system enhances axonal degeneration after peripheral nerve lesion in a transgenic mouse strain. J Neurochem 114:1007–1018PubMed

51.

Storch A, Odin P, Trender-Gerhard I et al (2010) Non-motor symptoms questionnaire and scale for Parkinson’s disease. Cross-cultural adaptation into the German language. Nervenarzt 81:980–985CrossRefPubMed

52.

Tenovuo O, Rinne UK, Viljanen MK (1984) Substance P immunoreactivity in the post-mortem parkinsonian brain. Brain Res 303:113–116CrossRefPubMed

53.

Toth C, Breithaupt K, Ge S et al (2010) Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 68:28–36CrossRefPubMed

54.

Toth C, Brown MS, Furtado S et al (2008) Neuropathy as a potential complication of levodopa use in Parkinson’s disease. Mov Disord 23:1850–1859CrossRefPubMed

55.

Ubeda-Banon I, Saiz-Sanchez D, de la Rosa-Prieto C et al (2010) Alpha-synucleinopathy in the human olfactory system in Parkinson’s disease: involvement of calcium-binding protein- and substance P-positive cells. Acta Neuropathol 119:723–735CrossRefPubMed

56.

Üçeyler N, Kafke W, Riediger N et al (2010) Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy. Neurology 74:1806–1813CrossRefPubMed

57.

Wakabayashi K, Takahashi H, Ohama E et al (1990) Parkinson’s disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 79:581–583CrossRefPubMed

58.

Wang N, Gibbons CH, Lafo J et al (2013) Alpha-synuclein in cutaneous autonomic nerves. Neurology 81:1604–1610CrossRefPubMed

Title: Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology
Authors: Kathrin Doppler
Sönke Ebert
Nurcan Üçeyler
Claudia Trenkwalder
Jens Ebentheuer
Jens Volkmann
Claudia Sommer
Publication date: 01-07-2014
Publisher: Springer Berlin Heidelberg
Published in: Acta Neuropathologica / Issue 1/2014
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-014-1284-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Epilepsies associated with focal cortical dysplasias (FCDs)

Tau protein mutation P364S in two sisters: clinical course and neuropathology with emphasis on new, composite neuronal tau inclusions

A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors

Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort

Cerebral cavernous malformations in the setting of focal epilepsies: pathological findings, clinical characteristics, and surgical treatment principles

Improved health-related quality of life outcomes associated with SHH subgroup medulloblastoma in SIOP-UKCCSG PNET3 trial survivors